HAMI 3379
Based on 1 publication(s) in Google Scholar
HAMI 3379 is a potent and selective CysLT2 receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation.
For research use only. We do not sell to patients.
- Purity: 98.64%
- CAS No.: 1245653-57-9
- Formula: C34H45NO8
- Molecular Weight:595.72
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Targeted Diversity Library
HY-L099
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) HAMI 3379
MoreAll Leukotriene Receptor Isoforms
More
Biological Activity
|
CysLT2 |
In a CysLT2 receptor reporter cell line, HAMI3379 antagonizes leukotriene D4- (LTD4-) and leukotriene C4- (LTC4-) induced intracellular calcium mobilization with IC50 values of 3.8 nM and 4.4 nM respectively. HAMI3379 exhibits very low potency on a recombinant CysLT1 receptor cell line (IC50>10000 nM). HAMI3379 does not exhibit any agonistic activity on both CysLT receptor cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
HAMI3379 (0.1 mg/kg; ip) administered at 0 and 1 h after reperfusion reduces infarct volume, attenuated brain edema, reduced neurological score, and increased holdingangle[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats (250-300 g) after MCAO[2]
-
Dosage:0.025, 0.05, 0.1, 0.2, 0.4 mg/kg
-
Administration:IP
-
Result:Significantly reduced the infarct volume and percentage increase inthe ischemic/contralateral hemispheric ratio (an index ofbrain edema) with 0.1-0.4 mg/kg.
Significantly reduced the neurological deficit score.
Chemical Information
-
CAS No. 1245653-57-9
-
Appearance Solid
-
Molecular Weight 595.72
-
Formula C34H45NO8
-
Color White to off-white
-
SMILES
O=C(O)C1=CC=C(OCCCC2=CC=C(OCCCCOC3CCCCC3)C=C2)C(C(N[C@@H]4C[C@@H](C(O)=O)CCC4)=O)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
DMSO : 100 mg/mL (167.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. F Wunder, et al. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol. 2010 May;160(2):399-409. [Content Brief]
[2]. Q J Shi, et al. HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats. Neuroscience. 2015 Apr 16;291:53-69. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6786 mL | 8.3932 mL | 16.7864 mL | 41.9660 mL |
| 5 mM | 0.3357 mL | 1.6786 mL | 3.3573 mL | 8.3932 mL | |
| 10 mM | 0.1679 mL | 0.8393 mL | 1.6786 mL | 4.1966 mL | |
| 15 mM | 0.1119 mL | 0.5595 mL | 1.1191 mL | 2.7977 mL | |
| 20 mM | 0.0839 mL | 0.4197 mL | 0.8393 mL | 2.0983 mL | |
| 25 mM | 0.0671 mL | 0.3357 mL | 0.6715 mL | 1.6786 mL | |
| 30 mM | 0.0560 mL | 0.2798 mL | 0.5595 mL | 1.3989 mL | |
| 40 mM | 0.0420 mL | 0.2098 mL | 0.4197 mL | 1.0492 mL | |
| 50 mM | 0.0336 mL | 0.1679 mL | 0.3357 mL | 0.8393 mL | |
| 60 mM | 0.0280 mL | 0.1399 mL | 0.2798 mL | 0.6994 mL | |
| 80 mM | 0.0210 mL | 0.1049 mL | 0.2098 mL | 0.5246 mL | |
| 100 mM | 0.0168 mL | 0.0839 mL | 0.1679 mL | 0.4197 mL |
HAMI 3379 Related Classifications
HY-112248A Related Classifications
Powered by Bioz